The European Medicines Agency (EMA) has approved an additional subcutaneous administration option for Takhzyro (lanadelumab) for patients aged 12 years and above with recurrent attacks of hereditary angioedema (HAE)

Takeda announced that the European Medicines Agency (EMA) has approved an additional 2 mL pre-filled pen option for Takhzyro (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (HAE).

The additional subcutaneous administration option expands Takeda’s offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their quality of life.

Irmgard Andresen, Global Medical Lead HAE at Takeda, said: “HAE affects an estimated 1 in 50,000 people worldwide and is often under recognised, under diagnosed and under treated. We welcome the swift approval by the EMA on this additional subcutaneous administration option. HAE patients 12 years and older now have an additional individualized treatment option available to them.”

(Source: Takeda)